FDA Cites J&J Duragesic Promotion For Misleading Safety Profile

Reports from a national drug abuse surveillance database are not sufficient basis for comparative safety claims between the Duragesic patch and other pain agents, FDA says. The agency asks J&J to devise a corrective action plan for a violative professional file card that was distributed beginning in 2003.